Company: INDP
Filing Date: 2025-06-13
Form Type: 8-K
Source: 0001641172-25-014972
Chunk: 2

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-06-13
Form: 8-K
Item: Item 1.01
Chunk 2
---
 to 12.0% of the gross proceeds received by the Company
from the offering, and a non-accountable expense of $25,000. In addition, Paulson is entitled to certain tail rights for a period of
one year following the termination or expiration of the PAA. The Placement Agent will also receive warrants (the “ Placement
Agent Warrants”) to purchase a number of shares of the Company’s Common Stock equal to 12.0% of the Conversion
Shares issuable upon conversion of the Notes sold in the offering. The Placement Agent Warrants will have the same terms as
the Warrants (except that the Placement Agent Warrants contain a cashless exercise feature) and expire on the fifth anniversary of
the issue date. The PAA contains certain customary representations and warranties and indemnification obligations of the Company and
Paulson.

This
Form 8-K shall not constitute an offer to sell or the solicitation of any offer to buy the securities discussed herein, nor shall there
be any offer, solicitation or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state.